Medicare Enrolled
Dr. Rajasree Ajay, M.D.
Hematology & Oncology · Galloway, NJ
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Ajay from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Ajay?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Ajay
Dr. Rajasree Ajay is a hematology & oncology specialist in Galloway, NJ, with 20 years of NPI registration. Based on federal Medicare data, Dr. Ajay performed 171,953 Medicare services across 2,893 unique beneficiaries.
Between the years covered by Open Payments, Dr. Ajay received a total of $2,303 from 42 pharmaceutical and/or device companies across 140 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Ajay is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 3% volume in NJ
$2,303 industry payments
Medicare Practice Summary
Medicare Utilization ↗171,953
Medicare services
Top 3% in NJ for hematology & oncology
2,893
Unique beneficiaries
$5
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~8,598 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
114,000 | $1 | $2 |
| Denosumab injection (Prolia/Xgeva) | 12,780 | $18 | $30 |
| Anti-nausea injection (aprepitant) | 8,450 | $1 | $5 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
6,802 | $0 | $3 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
6,700 | $6 | $30 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
5,820 | $6 | $30 |
| Anti-nausea injection (Aloxi/palonosetron) | 2,360 | $1 | $50 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
2,276 | $7 | $55 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
2,201 | $8 | $20 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
1,746 | $1 | $10 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,740 | $101 | $175 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
1,331 | $24 | $100 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
1,090 | $12 | $35 |
| Anti-nausea injection (ondansetron/Zofran) | 1,080 | $0 | $5 |
| Pegfilgrastim-cbqv injection An injection of pegfilgrastim-cbqv, a biosimilar medication, administered at a dose of 0.5 mg. |
648 | $107 | $600 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
460 | $112 | $270 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
447 | $1 | $10 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
312 | $1 | $4 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
309 | $1 | $10 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
268 | $23 | $100 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
240 | $52 | $185 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
188 | $1 | $20 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
140 | $9 | $75 |
| Prothrombin time test (blood clotting) A laboratory test that measures how long it takes for blood to clot. This procedure evaluates the body's coagulation process. |
118 | $4 | $20 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
95 | $11 | $75 |
| New patient office visit, complex (60-74 min) | 70 | $170 | $300 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
67 | $83 | $200 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
64 | $6 | $200 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
47 | $125 | $225 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
47 | $144 | $250 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
44 | $2 | $45 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
13 | $77 | $105 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
68.6% high complexity
27.3% medium
4.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$2,303
Total received (2018-2024)
Avg $329/year across 7 years
Bottom 45% in NJ for hematology & oncology
42
Companies
140
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$1,930 (83.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$373 (16.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$340
2023
$135
2022
$306
2021
$38
2020
$173
2019
$570
2018
$742
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
SEAGEN INC.
$99
PFIZER INC.
$92
ARRAY BIOPHARMA INC
$23
ADC Therapeutics America, Inc.
$22
Mirati Therapeutics, Inc.
$21
AstraZeneca Pharmaceuticals LP
$19
Novartis Pharmaceuticals Corporation
$18
Bayer Healthcare Pharmaceuticals Inc.
$17
Janssen Biotech, Inc.
$16
Exelixis Inc.
$14
Top 3 companies account for 62.7% of 2024 payments
All-time payments by company (2018-2024) ›
PFIZER INC.
$197
Takeda Pharmaceuticals U.S.A., Inc.
$174
Novartis Pharmaceuticals Corporation
$150
Genentech USA, Inc.
$139
AstraZeneca Pharmaceuticals LP
$135
Janssen Biotech, Inc.
$125
Incyte Corporation
$111
E.R. Squibb & Sons, L.L.C.
$107
SEAGEN INC.
$99
Astellas Pharma US Inc
$77
Daiichi Sankyo Inc.
$74
Amgen Inc.
$72
Janssen Pharmaceuticals, Inc
$66
Bayer HealthCare Pharmaceuticals Inc.
$57
GENZYME CORPORATION
$56
Seagen Inc.
$49
Sirtex Medical Inc
$49
Seattle Genetics, Inc.
$49
ADC Therapeutics America, Inc.
$41
Bayer Healthcare Pharmaceuticals Inc.
$39
Foundation Medicine, Inc.
$39
Pharmacyclics LLC, An AbbVie Company
$37
Regeneron Healthcare Solutions, Inc.
$31
Exelixis Inc.
$28
ABBVIE INC.
$27
Lilly USA, LLC
$26
Merck Sharp & Dohme Corporation
$25
ARRAY BIOPHARMA INC
$23
Mirati Therapeutics, Inc.
$21
Dova Pharmaceuticals
$18
Celgene Corporation
$16
Gilead Sciences, Inc.
$16
Otsuka America Pharmaceutical, Inc.
$15
Alexion Pharmaceuticals, Inc.
$15
EISAI INC.
$14
EMD Serono, Inc.
$13
Coherus Biosciences Inc.
$13
Kyowa Kirin, Inc.
$12
Helsinn Therapeutics (U.S.), Inc.
$12
Verastem, Inc.
$12
Epizyme, Inc.,
$12
Fortovia Therapeutics, Inc.
$12
Top 3 companies account for 22.6% of all-time payments
Associated products mentioned in payments ›
6 · ADCETRIS · AKYNZEO · Alecensa · Aliqopa · Avastin · BOSULIF · BRAFTOVI · Bavencio · CABOMETYX · CALQUENCE · Cabometyx · Copiktra · DARZALEX · Doptelet · ELIQUIS · ELREXFIO · ENHERTU · ERBITUX · ERLEADA · FARESTON · FOUNDATIONONE · GAZYVA · Gazyva · Halaven · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · Imbruvica · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LUPRON DEPOT · MEKINIST · MONJUVI · NINLARO · Nubeqa · OPDIVO · PADCEV · Padcev · Perjeta · Revlimid · SIR-Spheres Microspheres · SOLIRIS · SPRYCEL · SUTENT · Stivarga · TAFINLAR · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TUKYSA · TUMOR LYSIS SYNDROME - DISEASE · Udenyca · VELCADE · VENCLEXTA · VERZENIO · Vectibix · XALKORI · XARELTO · XTANDI · Xofigo · Zydelig
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (84%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
15
Per 100K population
5.5
County median income
$76,819
Nearest hospital
ATLANTICARE REGIONAL MEDICAL CENTER - CITY CAMPUS
7.2 mi
7.2 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Ajay is a mixed practice specialist, with above-average Medicare volume (top 3% in NJ), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Ajay experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Ajay performed 114,000 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Ajay receive payments from pharmaceutical companies?
Yes. Dr. Ajay received a total of $2,303 from 42 companies across 140 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Ajay's costs compare to other hematology & oncology specialists in Galloway?
Dr. Ajay's average Medicare payment per service is $5. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Ajay) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Galloway
Browse hematology & oncology specialists in Galloway ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in NJ
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in NJ
Which NJ hematology & oncology specialists receive the most from drug and device companies.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
Takeda Pharmaceuticals U.S.A., Inc. Payments to Doctors
See all physicians who received payments from Takeda Pharmaceuticals U.S.A., Inc.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology